Immunocore (IMCR) Competitors $29.92 +0.05 (+0.17%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$29.90 -0.03 (-0.08%) As of 02/21/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends IMCR vs. TLX, ELAN, LNTH, NUVL, CYTK, VRNA, GRFS, TGTX, KRYS, and SWTXShould you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Telix Pharmaceuticals Limited American Depositary Shares (TLX), Elanco Animal Health (ELAN), Lantheus (LNTH), Nuvalent (NUVL), Cytokinetics (CYTK), Verona Pharma (VRNA), Grifols (GRFS), TG Therapeutics (TGTX), Krystal Biotech (KRYS), and SpringWorks Therapeutics (SWTX). These companies are all part of the "pharmaceutical products" industry. Immunocore vs. Telix Pharmaceuticals Limited American Depositary Shares Elanco Animal Health Lantheus Nuvalent Cytokinetics Verona Pharma Grifols TG Therapeutics Krystal Biotech SpringWorks Therapeutics Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, community ranking, media sentiment, valuation, risk, analyst recommendations and institutional ownership. Does the media favor TLX or IMCR? In the previous week, Telix Pharmaceuticals Limited American Depositary Shares had 2 more articles in the media than Immunocore. MarketBeat recorded 5 mentions for Telix Pharmaceuticals Limited American Depositary Shares and 3 mentions for Immunocore. Immunocore's average media sentiment score of 0.99 beat Telix Pharmaceuticals Limited American Depositary Shares' score of 0.28 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals Limited American Depositary Shares 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Immunocore 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor TLX or IMCR? Immunocore received 63 more outperform votes than Telix Pharmaceuticals Limited American Depositary Shares when rated by MarketBeat users. However, 100.00% of users gave Telix Pharmaceuticals Limited American Depositary Shares an outperform vote while only 73.33% of users gave Immunocore an outperform vote. CompanyUnderperformOutperformTelix Pharmaceuticals Limited American Depositary SharesOutperform Votes3100.00% Underperform VotesNo VotesImmunocoreOutperform Votes6673.33% Underperform Votes2426.67% Which has higher valuation and earnings, TLX or IMCR? Telix Pharmaceuticals Limited American Depositary Shares has higher revenue and earnings than Immunocore. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelix Pharmaceuticals Limited American Depositary Shares$637.08M10.31N/AN/AN/AImmunocore$296.31M5.05-$55.29M-$0.95-31.49 Do insiders & institutionals believe in TLX or IMCR? 84.5% of Immunocore shares are owned by institutional investors. 9.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is TLX or IMCR more profitable? Telix Pharmaceuticals Limited American Depositary Shares has a net margin of 0.00% compared to Immunocore's net margin of -15.87%. Telix Pharmaceuticals Limited American Depositary Shares' return on equity of 0.00% beat Immunocore's return on equity.Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals Limited American Depositary SharesN/A N/A N/A Immunocore -15.87%-12.84%-5.09% Do analysts recommend TLX or IMCR? Telix Pharmaceuticals Limited American Depositary Shares currently has a consensus price target of $22.00, indicating a potential upside of 12.82%. Immunocore has a consensus price target of $65.64, indicating a potential upside of 119.37%. Given Immunocore's higher probable upside, analysts clearly believe Immunocore is more favorable than Telix Pharmaceuticals Limited American Depositary Shares.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telix Pharmaceuticals Limited American Depositary Shares 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Immunocore 1 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.54 SummaryTelix Pharmaceuticals Limited American Depositary Shares beats Immunocore on 9 of the 15 factors compared between the two stocks. Get Immunocore News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCR vs. The Competition Export to ExcelMetricImmunocoreBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.49B$3.13B$5.77B$8.98BDividend YieldN/A1.57%4.78%3.85%P/E Ratio-31.4930.1126.4618.82Price / Sales5.05386.73453.2580.30Price / CashN/A183.5344.0437.47Price / Book4.033.567.634.64Net Income-$55.29M-$71.72M$3.18B$245.69M7 Day Performance1.08%-2.46%-1.91%-2.66%1 Month Performance-3.55%-0.25%-0.19%-2.15%1 Year Performance-56.91%-12.31%16.70%12.90% Immunocore Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCRImmunocore1.4267 of 5 stars$29.92+0.2%$65.64+119.4%-57.4%$1.49B$296.31M-31.49320TLXTelix Pharmaceuticals Limited American Depositary SharesN/A$17.19-0.6%$22.00+28.0%N/A$5.79B$637.08M0.00N/ANews CoverageGap UpELANElanco Animal Health4.0515 of 5 stars$11.26-3.4%$16.29+44.7%-31.9%$5.57B$4.42B28.159,300Analyst ForecastLNTHLantheus4.5798 of 5 stars$79.94-2.5%$131.86+64.9%+37.9%$5.56B$1.30B13.30700Analyst RevisionPositive NewsNUVLNuvalent2.1211 of 5 stars$77.93-3.7%$112.36+44.2%-3.7%$5.54BN/A-22.4640Upcoming EarningsInsider TradeCYTKCytokinetics4.1857 of 5 stars$46.16+10.9%$82.00+77.6%-34.3%$5.45B$7.53M-8.58250High Trading VolumeVRNAVerona Pharma1.9349 of 5 stars$64.21+4.1%$57.14-11.0%+309.6%$5.13B$460,000.00-33.4430GRFSGrifols1.9016 of 5 stars$7.32-2.0%N/A-14.9%$5.03B$7.13B6.2023,737Upcoming EarningsTGTXTG Therapeutics4.4797 of 5 stars$30.71-0.1%$40.67+32.4%+137.2%$4.78B$233.66M-307.07290Positive NewsKRYSKrystal Biotech4.4745 of 5 stars$153.24-1.6%$206.67+34.9%+73.9%$4.41B$50.70M86.58210Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageSWTXSpringWorks Therapeutics1.2418 of 5 stars$57.43-2.0%$70.83+23.3%+18.4%$4.27B$5.45M-14.80230Earnings ReportAnalyst ForecastInsider TradeNews Coverage Related Companies and Tools Related Companies TLX Competitors ELAN Competitors LNTH Competitors NUVL Competitors CYTK Competitors VRNA Competitors GRFS Competitors TGTX Competitors KRYS Competitors SWTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMCR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
